SK Discovery, a KOSPI-listed company, announced on the 14th that its subsidiary SK Plasma will invest approximately 35.2 billion KRW in an Indonesian pharmaceutical manufacturing affiliate (PT. SKPLASMA CORE INDONESIA).
After the investment, the equity stake will be 29.6%.
SK Discovery explained the purpose of this investment as "additional equity investment for the establishment and leading operation of a local blood product factory."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
